---
title: "CanSino Biologics Inc. (688185.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688185.SH.md"
symbol: "688185.SH"
name: "CanSino Biologics Inc."
industry: "Biotechnology"
datetime: "2026-05-21T01:33:10.949Z"
locales:
  - [en](https://longbridge.com/en/quote/688185.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688185.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688185.SH.md)
---

# CanSino Biologics Inc. (688185.SH)

## Company Overview

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.cansinotech.com.cn](https://www.cansinotech.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.49)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 30 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 28.97% |  |
| Net Profit YoY | 99.54% |  |
| P/B Ratio | 3.25 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 16017113944.75 |  |
| Revenue | 1123024932.93 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -0.02% | D |
| Profit Margin | -0.09% | D |
| Gross Margin | 80.94% | A |
| Revenue YoY | 28.97% | A |
| Net Profit YoY | 99.54% | A |
| Total Assets YoY | -10.60% | E |
| Net Assets YoY | 0.55% | C |
| Cash Flow Margin | -3753.26% | E |
| OCF YoY | 28.97% | A |
| Turnover | 0.15 | D |
| Gearing Ratio | 29.54% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CanSino Biologics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "28.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "99.54%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.25",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "16017113944.75",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1123024932.93",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-0.02%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.09%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "80.94%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "28.97%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "99.54%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.60%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.55%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-3753.26%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "28.97%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.15",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "29.54%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15500.79 | 83/81 | 620.52 | 606.07 | 591.45 |
| PB | 3.17 | 47/81 | 3.93 | 3.42 | 3.15 |
| PS (TTM) | 13.91 | 60/81 | 20.53 | 17.44 | 16.26 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-23T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 63.99 |
| Highest Target | 80.00 |
| Lowest Target | 71.72 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688185.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688185.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688185.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**